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Abstract
Background: A substantial number of patients clinically diagnosed with Alzheimer’s disease do not harbor amyloid
pathology. We analyzed the presence and extent of tau deposition and neurodegeneration in amyloid-positive (AD)
and amyloid-negative (nonAD) ADNI subjects while also taking into account age of onset (< or > 65 years) as we
expected that the emerging patterns could vary by age and presence or absence of brain amyloidosis.
Methods: One hundred and ten early-onset AD (EOAD), 121 EOnonAD, 364 late-onset AD (LOAD), and 175
LOnonAD mild cognitive impairment (MCI) and dementia (DEM) subjects were compared to 291 ADNI amyloid-
negative control subjects using voxel-wise regression in SPM12 with cluster-level family-wise error correction at
pFWE < 0.05). A subset of these subjects also received
18F-flortaucipir scans and allowed for analysis of global tau
burden.
Results: As expected, relative to LOAD, EOAD subjects showed more extensive neurodegeneration and tau
deposition in AD-relevant regions. EOnonADMCI showed no significant neurodegeneration, while EOnonADDEM
showed bilateral medial and lateral temporal, and temporoparietal hypometabolism. LOnonADMCI and LOnonADDEM
showed diffuse brain atrophy and a fronto-temporo-parietal hypometabolic pattern. LOnonAD and EOnonAD
subjects failed to show significant tau binding.
Conclusions: LOnonAD subjects show a fronto-temporal neurodegenerative pattern in the absence of tau binding,
which may represent underlying hippocampal sclerosis with TDP-43, also known as limbic-predominant age-related
TDP-43 encephalopathy (LATE). The hypometabolic pattern observed in EOnonADDEM seems similar to the one
observed in EOADMCI. Further investigation into the underlying etiology of EOnonAD is warranted.
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sclerosis, Limbic-predominant age-related TDP-43 encephalopathy, LATE
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Introduction
An estimated 5.8 million people in the USA are cur-
rently diagnosed with Alzheimer’s disease (AD) [1]. Even
when rendered by dementia experts, the clinical diagno-
sis of AD shows only modest accuracy [2]. Twenty-nine
to 56% of clinically diagnosed AD patients are AD
phenocopies that fail to show AD pathology upon post-
mortem examination [2]. With the development of
amyloid tracers for positron emission tomography
(PET), we can now readily distinguish true AD cases
from amyloid-negative AD phenocopies (nonAD).
Ninety-seven percent of all AD cases have symptom on-
set at the age of 65 or older and are classified as “late-on-
set” (LO), while the remaining 3% have symptom onset
before the age of 65 and are termed “early-onset” (EO) [1,
3, 4]. Pathologically, patients who are younger at disease
onset show greater pathological burden [5–9]. Magnetic
resonance imaging (MRI), 18F-fluorodeoxyglucose (FDG)
PET, and 18F-flortaucipir PET (tau PET) studies have
shown that EO Alzheimer’s subjects (EOAD) have more
extensive atrophy, hypometabolism, and tau burden com-
pared to LO Alzheimer’s subjects (LOAD) [10–14]. More
advanced pathologic burden in EOAD has been associated
with more aggressive clinical course and is more likely to
have an atypical presentation [15–18]. To our knowledge
to date, the imaging biomarker profiles of early-onset
nonAD (EOnonAD) have not been studied.
The Alzheimer’s Disease Neuroimaging Initiative (ADNI)
is a multisite, longitudinal study that collects standardized
imaging, genetic, clinical, and fluid biomarkers from clinic-
ally diagnosed amnestic mild cognitive impairment (MCI),
clinically diagnosed Alzheimer’s dementia (DEM), and cog-
nitively normal (CN) control subjects as a part of a global
research effort to better understand LOAD. While the
majority of ADNI subjects are older than 65 years, ADNI
contains a sizeable cohort of amnestic EO MCI or
DEM subjects (age of symptom onset < 65 years). The
addition of amyloid imaging in the ADNI-GO/2 funding
stages allowed researchers to ascertain the amyloid PET
status of all ADNI participants and provided researchers
the opportunity to study the biomarker-validated AD and
nonAD phenocopies in greater detail.
In this study, our aim was to ascertain the extent and se-
verity of tau and neurodegenerative pathology measured
with tau PET, FDG PET, and MRI in EO and LO ADNI
cohorts stratified by amyloid status as follows: EOAD
MCI and DEM (EOADMCI; EOADDEM), EOnonAD MCI
and DEM (EOnonADMCI; EOnonADDEM), LOAD MCI
and DEM (LOADMCI; LOADDEM), and LOnonAD MCI
and DEM (LOnonADMCI; LOnonADDEM). We hypothe-
sized that EOAD and EOnonAD subjects would have
more severe neurodegeneration and greater tau burden
relative to their LO counterparts, indicative of the greater
disease burden likely required to have equivalent
impairment to the significantly older LO group. We also




Data used in the preparation of this article were obtained
from the ADNI database (adni.loni.usc.edu). ADNI was
launched in 2003 as a public-private partnership, led by
Principal Investigator Michael W. Weiner, MD. The pri-
mary goal of ADNI has been to test whether serial MRI,
PET, other biological markers, and clinical and neuro-
psychological assessments can be combined to accurately
measure and predict the progression of MCI and Alzhei-
mer’s dementia. ADNI has undergone three complete
funding cycles to date, ADNI1, ADNI-GO, and ADNI2,
and is now in the ADNI3 cycle. ADNI-GO, ADNI2, and
ADNI3 included 18F-florbetapir amyloid PET imaging.
The clinical and biomarker characteristics of the ADNI
cohort have been previously published [19]. ADNI has en-
rolled clinically diagnosed CN, amnestic MCI, and amnestic
DEM subjects. Probable AD DEM diagnosis is based on the
National Institute of Neurological and Communicative Dis-
orders and Stroke and the AD and Related Disorders Asso-
ciation (NINCDS-ADRDA) criteria [20]. Probable AD DEM
subjects were 56 to 90 years old at enrollment, scored be-
tween 20 and 26 on the Mini-Mental State Examination
(MMSE) [21] and 0.5–1 on the Clinical Dementia Rating
(CDR) global score [22]. Subjects diagnosed as amnestic
MCI ranged from 55 to 91 years old at enrollment, had no
significant functional impairment, scored between 24 and 30
on the MMSE, had a global CDR of 0.5 (memory score ≥
0.5), and had impairment on Wechsler Memory Scale – Lo-
gical Memory II test [23]. CN subjects had MMSE between
24 and 30 and a global CDR of 0 and did not meet criteria
for MCI or DEM. Subjects were excluded due to inability to
undergo MRI or if they had other neurological disorders, ac-
tive depression, or history of psychiatric diagnosis, alcohol,
or substance dependence within the past 2 years, less than 6
years of education or were not fluent in English or Spanish.
The full list of inclusion/exclusion criteria may be accessed
in the online ADNI protocol (http://www.adni-info.org/Sci-
entists/ADNIStudyProcedures.html). Written informed con-
sent was obtained from all participants, and the institutional
review board (IRB) at all ADNI sites have reviewed and ap-
proved ADNI data collection protocol.
For our analysis, we used 231 EO subjects with reported
age of symptom onset ≤ 65 years from the ADNI database
with available 18F-florbetapir amyloid PET or CSF Aβ data
(219 of the 231 received 18F-Florbetapir PET, while the
remaining 12 had CSF Aβ data). One hundred seventy-
three EO subjects met criteria for MCI and 58 for DEM.
Sixty MCI and 50 DEM were amyloid-positive (EOADMCI
and EOADDEM), and 113 and 8, respectively, were
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amyloid-negative (EOnonADMCI and EOnonADDEM)
based on previously validated 18F-florbetapir global means
standard uptake volume ratio (SUVR) cut-off of 1.17 [24]
or a CSF Aβ1–42 level < 192 pg/ml [25]. The subset with
tau PET (18F-Flortaucipir) included 10 EOADMCI, 7
EOADDEM, 38 EOnonADMCI, and 3 EOnonADDEM.
LO subjects included had either 18F-florbetapir amyloid
PET (488/539 subjects) or CSF Aβ data (51/539 subjects),
and all had FDG PET and MR imaging. Special care was
taken to ensure that no LO diagnostic group was signifi-
cantly more or less cognitively impaired than their EO coun-
terpart (measured by MMSE) by removing outlier subjects,
resulting in 539 subjects. Three hundred sixty-seven met cri-
teria for MCI and 172 for DEM. Two hundred sixteen LO
MCI and 148 LO DEM were amyloid-positive (LOADMCI
and LOADDEM), while 151 LO MCI and 24 LO DEM were
amyloid-negative (LOnonADMCI; LOnonADDEM). The sub-
set with tau PET included 53 LOADMCI, 27 LOADDEM, 51
LOnonADMCI, and 2 LOnonADDEM. Due to the low num-
bers of EO and LO nonADDEM subjects with
18F-flortaucipir
scans (3 and 2, respectively), they were grouped together
with the EO and LOnonADMCI, resulting in 41 EOnonAD
and 53 LOnonAD subjects in the tau comparisons.
Since EO and LO groups cannot be directly compared
because neurodegenerative changes associated with aging
could inadvertently confound the results, we conducted
two sets of analyses. We first compared each EO and LO
group to the same CN comparison group comprised of
the 291 amyloid-negative (SUVR< 1.17) CN subjects
within the age range of 55 to 90 years old. This compari-
son allowed for a straightforward interpretation of the ef-
fect sizes as a measure of disease impact. Next, we
repeated the analyses comparing the LO and EO groups
to only the older (N = 146) and younger half (N = 145) of
CN, respectively. The latter results are presented in Add-
itional figures 1, 2, 3, and 4 and Additional tables 1 & 2.
MRI and PET acquisition and analyses
ADNI MRI and PET acquisition and preprocessing proto-
cols can be found at www.adni-info.org. The MRI data ac-
quisition and preprocessing have been previously
described elsewhere [20]. We downloaded preprocessed
MRI data from LONI IDA (https://ida.loni.usc.edu). Scans
were spatially warped to Montreal Neurological Institute
(MNI) space and segmented into gray matter (GM), white
matter, and CSF components using voxel-based morph-
ometry (VBM) in Statistical Parametric Mapping version
12 (SPM12), as described previously [26]. GM maps were
normalized and smoothed using 10-mm full-width half
maximum (FWHM) Gaussian kernel, which yielded gray
matter density (GMD) data. Intracranial volume (ICV)
was also calculated using FreeSurfer version 5.1.
PET scanners across sites were held to rigorous qualifica-
tions, calibration, and normalization standards as described
in detail elsewhere [22]. We downloaded preprocessed
amyloid, FDG PET, and tau PET data from LONI IDA
(https://ida.loni.usc.edu). The scans were already averaged,
aligned to standard space, re-sampled to a standard image
and voxel size (2mm× 2mm× 2mm), and smoothed to a
uniform resolution as previously described [27]. We aligned
the images to the corresponding MRI scan from the same
visit and normalized them to MNI space using parameters
obtained from the MRI segmentation using SPM12. PET
scans were intensity normalized to mean pons uptake for
FDG, whole cerebellum for amyloid and cerebellar crus for
tau PET, resulting in whole brain SUVR images as previ-
ously described [28, 29]. To assign subjects into groups by
amyloid status, we used an amyloid PET cutoff of SUVR ≥
1.17 or CSF Aβ1–42 level < 192 pg/ml [24, 25].
Statistical analyses
Clinical and demographic analyses
The statistical distribution of clinical and demographic char-
acteristics (age, education, global CDR, MMSE, and amyloid
PET mean global SUVR) were analyzed in SPSS version
24.2 using one-way ANOVA. ANOVA p values are listed in
the tables and Bonferroni-corrected multiple comparisons p
values are listed in the results text. APOE4 genotype and sex
frequency comparisons were done using a chi-square test
with two-sided p values. The alpha value for all comparisons
was p < 0.05. In addition, a mixed effects model was gener-
ated in SAS 9.4 to comparing change in cortical [18F]-florbe-
tapir SUVR to the CN group as a reference.
Parametric mapping
We used voxel-wise linear regression models in SPM12
to study the extent and severity of neurodegeneration
and tau burden in EO and LO AD and nonAD groups
relative to CN while controlling for age, sex, and educa-
tion. Additionally, in the MRI analyses, we covaried for
MRI field strength (1.5 T vs. 3 T) and ICV. Family-wise
error (FWE) cluster-level correction was applied to cor-
rect for multiple comparisons with a significance thresh-
old of p < 0.01. Because side-by-side interpretation of
significance maps generated with unequal sample sizes
can be misleading, we also derived β-coefficient maps to
demonstrate the effect sizes in each comparison, which




The demographic, neuropsychological, and amyloid bur-
den comparisons of the amyloid positive diagnostic
groups relative to CN are shown in Table 1. Our CN
were significantly older than the EOADMCI and EOAD-
DEM and significantly younger than the LOADMCI and
LOADDEM subjects (p < 0.001, both). The CN subjects
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Table 1 EOAD and LOAD demographic comparisons to CN. The comparisons were done using ANOVA and chi-square tests with
two-sided p values. The Bonferroni-corrected pairwise differences relative to CN are discussed in the “Results” section. Significant p












Age, years, mean (SD) 74.3 (6.4) 65.4 (6.0) 64.7 (6.3) < 0.001 76.4 (5.8)** 78.3 (5.9)** < 0.001
Sex, male % 52.2 46.7 44.0 0.461 60.2 58.8 0.174
Education, years, mean (SD) 16.7 (2.6) 16.7 (2.8)* 15.6 (2.4)* 0.022 15.8 (2.8) 15.4 (3.0) < 0.001
% APOE ε4, 0/1/2 alleles 77/22/1 18/52/30 26/38/36 < 0.001 34/52/14 26/56/18 < 0.001
Global CDR, mean (SD) 0.02 (0.09) 0.50 (0.00)*** 0.87 (0.33)*** < 0.001 0.50 (0.16)*** 0.84 (0.36)*** < 0.001
MMSE, mean (SD) 29.0 (1.3) 27.8 (1.8)*** 22.5 (3.3)*** < 0.001 27.4 (1.9)*** 23.0 (2.8)*** < 0.001
Global cortical [18F]-florbetapir
SUVR, mean (SD)
1.03 (0.06) 1.41 (0.15)* 1.48 (0.13)* < 0.001 1.43 (0.17)* 1.47 (0.16)* < 0.001
Change in cortical [18F]-florbetapir
SUVR referenced to CN (p value)
ref 0.0155 (0.0352) 0.0079 (0.5071) N/A 0.0078 (0.1449) 0.0003 (0.9692) N/A
Tau scans, N 126 10 7 N/A 53 27 N/A
*MCI and DEM significantly different at p < 0.05
**MCI and DEM significantly different at p < 0.01
***MCI and DEM significantly different at p < 0.001
Table 2 EO vs. LO demographic comparisons. The comparisons were done using ANOVA and chi-square tests with two-sided p










Age, years, mean (SD) 65.4 (6.0) 76.4 (5.8) < 0.001 65.5 (5.8) 77.6 (6.2) < 0.001
Sex, male % 46.7 60.2 0.065 50.4 59.6 0.138
Education, years, mean (SD) 16.7 (2.8) 15.8 (2.8) 0.021 16.2 (2.5) 16.3 (2.5) 0.848
% APOE e4, 0/1/2 alleles 18/52/30 34/52/14 0.004 68/30/2 86/13/2 0.005
Global CDR, mean (SD) 0.50 (0.00) 0.50 (0.16) 0.823 0.46 (0.17) 0.48 (0.11) 0.167
MMSE, mean (SD) 27.8 (1.8) 27.4 (1.9) 0.229 28.6 (1.5) 28.4 (1.6) 0.175
Global cortical [18F]-florbetapir
SUVR, mean (SD)
1.41 (0.15) 1.43 (0.17) 0.315 1.03 (0.08) 1.01 (0.09) 0.115
Tau scans, N 10 53 N/A 38 51 N/A









Age, years, mean (SD) 64.7 (6.3) 78.3 (5.9) < 0.001 66.3 (5.8) 79.4 (5.8) < 0.001
Sex, male % 44.0 58.8 0.069 50.0 83.3 0.059
Education, years, mean (SD) 15.6 (2.4) 15.4 (3.0) 0.668 15.6 (3.5) 15.6 (3.0) 1.000
%APOE e4, 0/1/2 alleles 26/38/36 26/56/18 0.022 71/14/14 83/13/4 0.642
Global CDR, mean (SD) 0.87 (0.33) 0.84 (0.36) 0.579 0.69 (0.26) 0.83 (0.24) 0.155
MMSE, mean (SD) 22.5 (3.3) 23.0 (2.8) 0.283 23.0 (2.4) 23.6 (1.9) 0.453
Global cortical [18F]-florbetapir
SUVR, mean (SD)
1.48 (0.13) 1.47 (0.16) 0.616 1.04 (0.08) 1.01 (0.10) 0.485
Tau scans, N 7 27 N/A 3 2 N/A
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were significantly less impaired (global CDR and
MMSE), had significantly fewer APOE4 carriers, and had
a significantly lower [18F]-florbetapir SUVR compared to
all cognitively impaired AD groups (p < 0.001, all). In
addition, EOADDEM and both LOADMCI and LOADDEM
had significantly fewer years of education than the CN
group (p = 0.006, p < 0.001, and p < 0.001, resp). When
the data were split into younger and older subgroups,
the effects remained the same, except that LOADMCI
subjects were significantly younger (p < 0.001) and
LOADDEM no longer were significantly older or younger
than the CN group (Additional Table 1).
As expected, the EOADMCI and EOADDEM subjects
were significantly younger compared to the LOADMCI
and LOADDEM groups (p < 0.001, Table 2, top). Com-
pared to EOADMCI, LOADMCI had significantly fewer
years of education (p = 0.021). The EOADDEM and
LOADDEM groups showed similar education. Both
EOAD groups had a significantly higher percentage of
APOE ε4 homozygotes compared to LOAD subjects
(MCI p = 0.004, DEM p = 0.022). There were no signifi-
cant differences in global 18F-florbetapir SUVR, global
CDR, or MMSE between EO and LOAD groups.
Regional amyloid comparisons between the AD sub-
jects showed a significant difference (p = 0.044) in par-
ietal cortices and significant (p = 0.048) difference in
temporal amyloid SUVR between EOADMCI and EOAD-
DEM (Additional Table 2).
Imaging comparisons
The FWE cluster-level corrected maps of the MRI, FDG
PET, and tau PET comparisons of EOAD and LOAD
spectrum individuals to CN are shown in Fig. 1. The
same analyses limited to only subjects with tau PET
scans are shown in Additional Figure 1 while Additional
Figure 2 displays comparisons of EOAD and LOAD to
younger and older CN subgroups, respectively. The pat-
tern of neurodegeneration and tau deposition seen in
Fig. 1 and Additional Figures 1 and 2 are very similar
discounting the probability of exaggerated age or selec-
tion bias.
MRI (Fig. 1, top panel) The EOADMCI group showed
two significant clusters of atrophy in the left and right
medial and lateral temporal and left frontal cortices rela-
tive to the CN group (left cluster: cluster size k = 45,797,
cluster pFWE < 0.001; right cluster: k = 20,760, cluster
pFWE = 0.003). Compared to the CN group, the
LOADMCI cohort showed significant atrophy of the bi-
lateral medial and lateral temporal, temporoparietal, in-
sular, occipital, and frontal regions (single cluster k =
688,646, cluster pFWE < 0.001). The EOADMCI group
visually showed a larger effect size (i.e., more severe
atrophy) than LOADMCI in overlapping regions (see β-
coefficient maps in Fig. 1, top panel).
Both EOADDEM and LOADDEM showed extensive at-
rophy throughout the brain compared to CN (single
clusters, kEO = 1,541,575, kLO = 1,503,763, cluster pFWE <
0.001 for both). The significance and β-coefficient maps
show a stronger effect size (i.e., more severe atrophy) in
the EOADDEM than the LOADDEM group (see β-
coefficient maps in Fig. 1, top panel).
FDG PET (Fig. 1, middle panel) Compared to CN,
EOADMCI showed a significant hypometabolic cluster in
bilateral medial and lateral temporal and lateral, tempor-
oparietal cortices (k = 32,246, cluster pFWE < 0.001). Add-
itionally, there was a small cluster of hypometabolism in
bilateral dorsolateral prefrontal cortex (k = 3396, cluster
pFWE < 0.001). LOADMCI subjects showed hypometabo-
lism of the bilateral inferior temporal, medial and lateral
temporal, and parietal cortices as well as bilateral frontal
cortex (single cluster, k = 94,307, cluster pFWE < 0.001,
Fig. 1, middle panel).
Both the EOADDEM and LOADDEM groups showed ex-
tensive hypometabolism relative to CN in bilateral par-
ietal, temporal, and frontal lobes, as well as insular and
cingulate cortices (single clusters, kEO = 148,701, kLO =
185,998, cluster pFWE < 0.001 for both). As with the MRI
analysis, the EOADDEM group showed a stronger effect
size (i.e., more severe hypometabolism) than the LOAD-
DEM group (see β-coefficient maps in Fig. 1, middle panel).
Tau PET (Fig. 1, bottom panel) These analyses were
limited to the subset of individuals with available tau
PET imaging. Compared to the CN group, the EOADMCI
group had a significant cluster of tau binding covering
temporal, parietal, parietooccipital, and right frontal cor-
tices (k = 74,981, cluster pFWE < 0.001). An additional sig-
nificant cluster of tau binding was present in the left
prefrontal cortex (k = 9800, cluster pFWE < 0.001). The
LOADMCI cohort showed tau deposition in a similar pat-
tern (single cluster, k = 96,885, cluster pFWE < 0.001). The
beta coefficient maps demonstrated greater tau burden
in EOADMCI compared to LOADMCI (see β-coefficient
maps in Fig. 1, bottom panel).
EOADDEM showed tau binding in all cortical regions
save for the primary sensorimotor and visual cortices
(single cluster, k = 157,966, cluster pFWE < 0.001). LOAD-
DEM showed two significant clusters of tau binding—one
in the posterior association cortices (k = 67,260, cluster
pFWE < 0.001) and a smaller one in the bilateral pre-
frontal cortices (k = 4931, cluster pFWE < 0.001). The β-
coefficient maps show much more severe and extensive
tau deposition in EOADDEM compared to LOADDEM
(see β-coefficient maps in Fig. 1, bottom panel).
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Fig. 1 MRI (top), FDG PET (middle), and tau PET (bottom) comparisons between the AD groups and CN. The significance maps show p<0.05 thresholded
FWE cluster-level corrected results of EOADMCI (N=60), EOADDEM (N=50), LOADMCI (N=216), and LOADDEM (N=148) vs. CN (N=291). The results displayed
here are for all subjects with available scans in each modality
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NonAD analyses
Demographic comparisons
Direct comparisons of CN to EOnonADMCI, LOno-
nADMCI, EOnonADDEM, and LOnonADDEM showed the
expected significant difference in age, global CDR, and
MMSE (p < 0.001, Table 3). Compared to CN, LOno-
nADDEM had a greater proportion of men (p = 0.003)
and lower education (p = 0.044). Even when split in
younger and older subgroups, the age differences be-
tween CN and the respective disease groups remained
significant with the exception of LOnonADDEM (Add-
itional Table 3).
By definition, EOnonADMCI and EOnonADDEM were
significantly younger than the corresponding LOnonAD
groups (p < 0.001). The EOnonADMCI group had a
higher proportion of APOE ε4 carriers compared to the
LOnonADMCI group (p = 0.005). There were no signifi-
cant differences in sex, education, global CDR, MMSE,
or global 18F-florbetapir SUVR between the groups.
A closer look into regional amyloid differences among
amyloid-negative subjects revealed significant differences
between the LOnonADDEM group and CN, EOnonADMCI,
EOnonADDEM, and LOnonADMCI in parietal SUVR (p <
0.05 for all). No other region was significantly different.
Imaging comparisons
The FWE cluster-level corrected MRI, FDG PET, and
tau PET comparison maps of the nonAD groups to CN
are shown in Fig. 2. The same analyses limited to only
subjects with tau PET scans are shown in Additional
Figure 3, while Additional Figure 4 displays comparisons
of EOnonAD and LOnonAD to younger and older CN
subgroups, resp. The pattern of neurodegeneration and
tau deposition seen in Additional Figure 4 is largely
identical to the one in Fig. 2, with the exception of
emerging tau deposition in bilateral frontal and right
parietal lobes in EOnonAD when compared to the
young CN.
MRI (Fig. 2, top panel) EOnonAD showed no signifi-
cant atrophy compared to the CN group. LOnonADMCI
showed extensive atrophy in the bilateral medial and lat-
eral temporal, temporoparietal, parietooccipital, and
frontal cortices (single cluster, k = 569,219, cluster
pFWE < 0.001). LOnonADDEM had similarly widespread
atrophy showing two significant clusters—one in bilat-
eral temporoparietal and frontal cortices (k = 602,716,
cluster pFWE < 0.001) and another in the cerebellum (k =
13,494, cluster pFWE = 0.020). The largest effect size was
observed in LOnonADDEM with greatest predilection for
the medial and inferior temporal lobes (see β-coefficient
maps in Fig. 2, top panel).
FDG PET (Fig. 2, middle panel) Compared to CN,
EOnonADMCI showed no significant hypometabolism,
while the EOnonADDEM group showed three significant
clusters in left and right temporoparietal (left: k = 15,114,
cluster pFWE < 0.001; right: k = 6104, cluster pFWE <
0.001) and bilateral frontal cortices (single cluster, k =
3002, cluster pFWE < 0.001). LOnonADMCI showed a sig-
nificant cluster of hypometabolism in bilateral temporal
and prefrontal cortices (k = 24,278, cluster pFWE < 0.001).
A similar fronto-temporal pattern of hypometabolism
was also observed in LOnonADDEM; however, it also ex-
tended to the parietal lobes (single cluster, k = 78,550,
cluster pFWE < 0.001).
Table 3 EOnonAD and LOnonAD demographic comparisons to CN. The comparisons were done using ANOVA and chi-square tests
with two-sided p values. The Bonferroni-corrected pairwise differences relative to CN are discussed in the “Results” section. Significant












Age, years, mean (SD) 74.3 (6.4) 65.5 (5.8) 66.3 (5.8) < 0.001 77.6 (6.2) 79.4 (5.8) < 0.001
Sex, male % 52.2 50.4 50.0 0.944 59.6* 83.3* 0.008
Education, years, mean (SD) 16.7 (2.6) 16.2 (2.5) 15.6 (3.5) 0.095 16.3 (2.5) 15.6 (3.0) 0.037
% APOE ε4, 0/1/2 alleles 77/22/1 68/30/2 71/14/14 0.028 86/13/2 83/13/4 0.173
Global CDR, mean (SD) 0.02 (0.09) 0.46 (0.17)*** 0.69 (0.26)*** < 0.001 0.48 (0.11)*** 0.83 (0.24)*** < 0.001
MMSE, mean (SD) 29.0 (1.3) 28.6 (1.5)*** 23.0 (2.4)*** < 0.001 28.4 (1.6)*** 23.6 (1.9)*** < 0.001
Global cortical [18F]-florbetapir
SUVR, mean (SD)
1.03 (0.06) 1.03 (0.08) 1.04 (0.08) 0.214 1.01 (0.09) 1.01 (0.10) 0.160
Change in cortical [18F]-florbetapir










Tau scans, N 126 38 3 N/A 51 2 N/A
*MCI and DEM significantly different at p < 0.05
***MCI and DEM significantly different at p < 0.001
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Fig. 2 MRI (top), FDG PET (middle), and tau PET (bottom) comparisons between the nonAD groups and CN. The significance maps show p < 0.05
thresholded FWE cluster-level corrected results of EOnonADMCI (N = 113), EOnonADDEM (N = 8), LOnonADMCI (N = 151), and LOnonADDEM (N = 24)
vs. CN (N = 291). The results displayed here are for all subjects with available scans in each modality
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Tau PET (Fig. 2, bottom panel) Due to the small sam-
ple sizes, the EOnonAD and LOnonAD groups were not
split by disease stage. There was no significant tau bind-
ing in either EOnonAD or LOnonAD. As mentioned
above, EOnonAD showed tau deposition in bilateral
frontal (single cluster, k = 7215, cluster pFWE < 0.001) and
right parietal lobes (single cluster, k = 4664, cluster
pFWE < 0.001) when compared to young CN only (Add-
itional Figure 4).
Discussion
The current study aimed to map neurofibrillary, struc-
tural, and metabolic differences between EO and LO
MCI and DEM subjects stratified by amyloid positivity.
As expected, we found that EOADMCI and EOADDEM
subjects show more severe neurodegeneration and
greater tau deposition compared to LOADMCI and
LOADDEM, respectively, a finding that is consistent with
previous imaging reports [5–11, 14, 18], and with the
fact that EO individuals have a much more aggressive
disease course [15, 18].
The availability of amyloid PET imaging or CSF Aβ
measurements allowed us to identify nonAD cases that
were enrolled as Alzheimer’s phenocopies. While we
failed to find significant neurodegeneration in EOno-
nADMCI, we observed significant hypometabolism in
EOnonADDEM in the absence of significant atrophy, a
finding that could be indicative of synaptic dysfunction
before cellular loss. The lack of findings, particularly in
the EOnonADMCI subjects, where the neurodegenerative
changes are likely subtle, may be due to our inability to
properly account for age-related degeneration (despite
covarying for age during the analysis) when comparing
directly to the CN subjects who are significantly older.
In our EOnonADDEM subjects, the lack of significant at-
rophy may be due to a relatively small sample size, as
the beta-coefficient maps indicate a pattern of neurode-
generation similar to that seen in the FDG PET analysis.
Furthermore, the EOnonADDEM subjects may be a het-
erogeneous group of multiple etiologies, making detec-
tion of significant clusters of atrophy difficult.
LOnonAD cases showed pronounced atrophy and
hypometabolism with greatest predilection for the tem-
poral and frontal lobes. This pattern of neurodegenera-
tion has been reported in primary age-related tauopathy
(PART) and hippocampal sclerosis with TAR-DNA
binding protein 43 (TDP-43) inclusions (HS-TDP-43)
[30, 31]. Both conditions are highly prevalent among the
elderly with and without cognitive deficit [30, 31];
however, of these two, HS-TDP-43 (also known as
limbic-predominant age-related TDP-43 encephalopathy
(LATE) [32]) is the more likely etiology due to the lack
of tau binding in the medial temporal lobes which is ex-
pected in PART. It is worth noting that though 18F-
flortaucipir binds well to mature tangles in 3R+4R tauo-
pathies, such as in AD and PART [33, 34], further post
mortem studies are needed to say with confidence which
tauopathy tau variants can reliably be bound with
flortaucipir.
The hypometabolic pattern we observed in LOnonAD
fits well with previous pathologic and imaging reports of
LATE. TDP-43 inclusions and neurite deposits first ap-
pear in the hippocampal dentate granule cells, subicu-
lum, and the amygdala [31, 35, 36]. In more advanced
stages, TDP-43 pathology is also found in frontal and
temporal neocortex [31, 35, 36]. TDP-43 pathology is
extremely prevalent among cognitively impaired elderly
and is the stand-alone pathology in 4.2% of these cases
[31, 35, 37, 38]. Eighty-six percent of TDP-43-positive
cases have HS-TDP-43 [31, 39–41]. HS-TDP-43 often-
times show episodic and semantic memory dysfunction
[42], explaining how they could easily be diagnosed clin-
ically with AD. Individuals with HS-TDP-43 have greater
hippocampal atrophy and greater cognitive impairment
than those with HS without TDP-43 [35, 36, 39]. Add-
itional support for our hypothesis that our LOnonAD
subjects likely harbor HS-TDP-43 are the recent reports
that HS-TDP-43 cases show hypometabolic changes in
the medial and lateral temporal, posterior and middle
cingulate, precuneus, and prefrontal cortex [43], similar
to the FDG PET pattern we observed in LOnonADMCI
and LOnonADAD. Similar hypometabolic and atrophy
patterns involving medial and lateral temporal and pre-
frontal cortices were recently reported in two additional
clinic-pathologic studies [44, 45].
An additional possibility is that some LOnonAD sub-
jects may suffer from behavioral variant frontotemporal
dementia (bvFTD). However, this is less likely given the
mean age of our LOnonAD cohorts (77.6 and 79.4 years,
resp) and their amnestic predominant presentation at en-
rollment as required by ADNI (see http://www.adni-info.
org/Scientists/ADNIStudyProcedures.html). It is worth
noting, however, that in rare cases (10% of pathologically
confirmed bvFTD cases), patients presented with primar-
ily amnestic symptoms and some studies have even re-
ported as much as 25% of pathologically confirmed FTLD
cases to have a disease onset after the age of 65 [46, 47].
Several strengths and limitations of our study should
be noted. One of the strengths is the relatively large
sample size of EO subjects available through ADNI.
Additionally, ADNI employs meticulously standardized
clinical and imaging data collection, which is routinely
subjected to quality control. One of the limitations of
our analyses is the cross-sectional design and the meas-
urement of atrophy, which has a temporal component.
This means that we are actually measuring differences in
gray matter density, which implies atrophy, but is not
synonymous. Longitudinal analyses are needed to assess
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atrophy and metabolic changes over time. Additionally,
while the rigorous exclusion criteria employed in ADNI
are typical of clinical trials, this renders the ADNI’s
population as not representative of the general popula-
tion. Furthermore, there is very little post mortem data
currently available for ADNI, which means diagnosis of
AD largely lacks pathological verification. Finally, while
we are including the EOnonADDEM in our report for
completeness, one must keep in mind that the number
of subjects in this group is very small; thus, the findings
should be interpreted with caution. Larger research
studies such as the recently funded Longitudinal Early-
onset Alzheimer’s disease Study (LEADS) which will use
amyloid imaging and detect EOnonAD cases will be able
to define the neurodegenerative pattern in this group.
Conclusion
In conclusion, our study found a similar neurodegenera-
tive pattern between amnestic amyloid-positive EO and
LO MCI and DEM subjects. These processes were more
severe in the EO group indicating a more aggressive dis-
ease course. We also found that LOnonADDEM subjects
show anterior temporal neurodegeneration which might
reflect the presence HS-TDP-43 or LATE. In the ab-
sence of reliable in vivo TDP-43 biomarker, the only
feasible method of confirmation is through post-mortem
examination of the brains. Other large research consor-
tia such as the recently funded LEADS project will allow
us the opportunity to systematically study EOAD and
EOnonAD and further characterize these highly under-
studied disease states.
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